Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: Is it time to move on from zidovudine?

HIV Medicine

Volumn 10, Issue 7, 2009, Pages 397-406

  Foster, Caroline ^a   Lyall, H ^a   Olmscheid, B ^b   Pearce, G ^c   Zhang, S ^b   Gibb, D M ^d  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b GILEAD SCIENCES   (United States)

^c Gilead Sciences Europe Ltd   (United Kingdom)

^d MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Mother to child transmission; Nevirapine resistance; Tenofovir DF; Toxicity

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ENTECAVIR; GS 4331; INDINAVIR; LAMIVUDINE; LOPINAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ANEMIA; ANTIVIRAL SUSCEPTIBILITY; BIRTH DEFECT; BONE DISEASE; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION PREVENTION; INTRAUTERINE GROWTH RETARDATION; INTRAUTERINE INFECTION; MATERNAL BLOOD; NONHUMAN; PERINATAL DRUG EXPOSURE; PLACENTAL TRANSFER; PRIORITY JOURNAL; REVIEW; SECOND TRIMESTER PREGNANCY; SHORT COURSE THERAPY; SINGLE DRUG DOSE; TERATOGENESIS; THIRD TRIMESTER PREGNANCY; VIRUS TRANSMISSION;

ADENINE; ADULT; AFRICA SOUTH OF THE SAHARA; ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BONE DISEASES; CHILD; CHILD, PRESCHOOL; CONGENITAL ABNORMALITIES; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, VIRAL; FEMALE; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MACACA; MITOCHONDRIA; NEVIRAPINE; PHOSPHONIC ACIDS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; ZIDOVUDINE;

EID: 67650670689     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00709.x     Document Type: Review

References (67)

1. Gazzard BG on behalf of the BHIVA Treatment Guidelines Writing Group. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9: 563-608.
2. European AIDS Clinical Society. Guidelines for the Clinical Management and Treatment of HIV Infected Adults in Europe. June, 2008. Available at: http://www.europeanaidsclinicalsociety.org/guidelinespdf/ 1_Treatmentof_HIV_Infected_Adults.pdf (last accessed 15 April 2009) (last accessed 8 October 2008).
3. de Ruiter A, Mercey D, Anderson J et al. British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women. HIV Med 2008; 9: 452-502.
4. Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. July 8, 2008. Available at: http://aidsinfo.nih.gov/contentfiles/ PerinatalGL.pdf (last accessed 10 October 2008).
5. Guay LA, Musoke P, Fleming T et al. Intrapartum and neonatal single dose nevirapine compared with zidovudine for the prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 Randomised Trial. Lancet 1999; 354: 795-802.
6. Arrivé E, Newell ML, Ekouevi DK et al. for the Ghent Group on HIV in Women and Children. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: A meta-analysis. Int J Epidemiol 2007; 36: 1009-1021.
7. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40: 458-465.
8. European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: The health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr 2003; 32: 380-387.
9. Cooper ER, Charurat M, Mofenson L et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J AIDS 2002; 29: 484-494.
10. Centers for Disease Control and Prevention. Achievements in public health: Reduction in perinatal transmission of HIV infection -United States, 1985-2005. Mortal Morbid Wkly Rep 2006; 55: 592-597.
11. Foster C, Lyall H. Mother-to-child transmission of HIV-1: UK strategies for prevention. AIDS & Hepatitis Digest 2008; 124: 1-4.
12. Townsend C, Cortina-Borja M, Peckham C et al. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008; 22: 973-981.
13. Mofenson LM. Successes and challenges in the perinatal HIV-1 epidemic in the United States as illustrated by the HIV-1 serosurvey of childbearing women. Arch Pediatri Adolesc Med 2004; 158: 422-425.
14. Connor EM, Sperling RS, Gelber R et al. and the Paediatric AIDS Clinical Trial Group Protocol 076 Study Group. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331: 1173-1180.
15. Public Health Service Task Force. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. January 29, 2008. Available at http://aidsinfo.nih.gov/contentfiles/ AdultandAdolescentGL.pdf (last accessed 1 December 2008).
16. UNAIDS. Report on the global AIDS epidemic. 2008. Available at: http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/ 2008_Global_report.asp (last accessed 1 December 2008).
17. McIntyre JA, Martinson N, Grey GE for the Trial 1413 Investigator Team. Single-dose nevirapine combined with a short course of combivir for prevention of mother to child transmission of HIV-1 can significantly decrease the subsequent development of maternal and infant resistant virus. Antivir Ther 2005; 10(Suppl. 1): S4.
18. Chi BH, Sinkala M, Mbewe F et al. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: An open-label randomised trial. Lancet 2007; 370: 1698-1705.
19. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: Towards universal access. WHO Guidelines 2006. Available at: http://www.who.int/hiv/pub/guidelines/ pmtctguidelines3.pdf (last accessed 8 October 2008).
20. Cotter AM, Garcia AG, Duthely ML, Luke B, O'Sullivan MJ. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis 2006; 193: 1195-1201.
21. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS 2007; 21: 1019-1026.
22. Foster C, Lyall H. HIV and mitochondrial toxicity in children. J Antimicrob Chemother 2008; 61: 8-12.
23. The European Collaborative Study and the Swiss Mother and Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS 2000; 14: 2913-2920.
24. Tuomala RE, Shapiro DE, Mofenson LM et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002; 346: 1863-1870.
25. Martin F, Taylor GP. Increased rates of preterm delivery are associated with the initiation of highly active antiretroviral therapy during pregnancy: A single center cohort study. J Infect Dis 2007; 196: 558-561.
26. Antiretroviral Pregnancy Registry International Interim Report 1 January 1989-31 July 2008. Issued December 2008. Available at: http://www.APRegistry.com
27. Nightingale SL. From the FDA. JAMA 1998; 280: 1472.
28. Chersich MF, Urban MF, Venter FWD et al. Efavirenz use during pregnancy and for women of child-bearing potential. AIDS Res Ther 2006; 3: 11-16.
29. Moyle G. Mechanisms of HIV and nucleoside reverse transcriptase inhibitor injury to mitochondria. Antivir Ther 2005; 10(Suppl. 2): M47-M52.
30. Gallant JE, Pham PA. Tenofovir disoproxil fumarate (Viread) for the treatment of HIV infection. Expert Rev Anti Infect Ther 2003; 1: 415-422.
31. Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: Comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002; 46: 716-723.
32. Gerschenson M, Nguyen V, Ewings EL et al. Mitochondrial toxicity in fetal Erythrocebus patas monkeys exposed transplacentally to zidovudine plus lamivudine. AIDS Res Hum Retroviruses 2004; 20: 91-100.
33. Divi RL, Leonard SL, Kuo MM et al. Cardiac mitochondrial compromise in 1-yr-old Erythrocebus patas monkeys perinatally-exposed to nucleoside reverse transcriptase inhibitors. Cardiovasc Toxicol 2005; 5: 333-346.
34. Divi RL, Leonard SL, Kuo MM et al. Transplacentally exposed human and monkey newborn infants show similar evidence of nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity. Environ Mol Mutagen 2007; 48: 201-209.
35. Shiramizu B, Shikuma KM, Kamemoto L et al. Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy. J Acquir Immune Defic Syndr 2003; 32: 370-374.
36. Poirier MC, Divi RL, Al-Harthi L et al. for the Women and Infants Transmission Study (WITS) Group. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr 2003; 33: 175-183.
37. Blanche S, Tardieu M, Rustin P et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354: 1084-1089.
38. Barret B, Tardieu M, Rustin P et al. for the French Perinatal Cohort Study Group. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: Clinical screening in a large prospective cohort. AIDS 2003; 17: 1769-1785.
39. The Perinatal Safety Review Working Group. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: Absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. J Acquir Immune Defic Syndr 2000; 25: 261-268.
40. Giaquinto C, De Romeo A, Giacomet V et al. Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission. AIDS 2001; 15: 1074-1075.
41. Alimenti A, Burdge DR, Ogilvie GS et al. Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy. Pediatr Infect Dis J 2003; 22: 782-788.
42. Biesecker G, Karimi S, Desjardins J et al. Evaluation of mitochondrial DNA content and enzyme levels in tenofovir DF-treated rats, rhesus monkeys and woodchucks. Antiviral Res 2003; 58: 217-225.
43. Tarantal AF, Marthas ML, Shaw JP, Cundy K, Bischofberger N. Administration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): Safety and efficacy studies. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 323-333.
44. Tarantal AF, Castillo A, Ekert JE, Bischofberger N, Martin RB. Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta). J Acquir Immune Defic Syndr 2002; 29: 207-220.
45. Van Rompay KK, Brignolo LL, Meyer DJ et al. Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother 2004; 48: 1469-1487.
46. Van Rompay KK, Durand-Gasselin L, Brignolo LL et al. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: Summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother 2008; 52: 3144-3160.
47. Van Rompay KK, McChesney MB, Aguirre NL et al. Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection. J Infect Dis 2001; 184: 429-438.
48. VIREAD ® (tenofovir disoproxil fumarate) tablets. US Prescribing Information. Foster City, CA: Gilead Sciences Inc., 2008.
49. Wang LH, Begley J, Feng JY, Quinn J, Rousseau F. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing. 14th International AIDS Conference. Barcelona, Spain, July 2002 [Abstract 4546].
50. Emtriva ® (emtricitabine) capsules. US Prescribing Information. Foster City, CA: Gilead Sciences Inc., 2008.
51. Hawkins T, Veikley W, St. Claire R et al. Intracellular pharmacokinetics of tenofovir-DP and carbovir-TP in patients receiving triple nucleoside regimens. 5th International Workshop on Clinical Pharmacology of HIV Therapy. Rome, Italy, April 2004 [Abstract 5.11].
52. Bonora S, Gonzalez de Requena D, Chiesa E, et al. and the Target Study Group. Transplacental passage of tenofovir and other antiretrovirals at delivery. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 2007 [Abstract 738a].
53. Burchett S, Best B, Mirochnick M et al. and the PACTG P1026s Team. Tenofovir pharmacokinetics during pregnancy, at delivery and postpartum. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 2007 [Abstract 738b].
54. Rodman J, Flynn P, Shapiro D et al. and PACTG 394 Study Team. Pharmacokinetics (PK) and safety of tenofovir disoproxil fumarate (TDF) in HIV-1-infected pregnant women and their infants. 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, February 2006 [Abstract 708].
55. Hirt D, Urien S, Rey E et al. Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates: TEmAA ANRS 12109. 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 2008 [Abstract 47LB].
56. Arrive E, Chaix ML, Nerrienet E et al. The TEmAA ANRS 12109 phase II trial, step 1: Tolerance and viral resistance after single dose nevirapine and short course of tenofovir disoproxil fumarate and emtricitabine to prevent mother-to-child transmission of HIV-1. 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 2008 [Abstract 45b].
57. Fux CA, Christen A, Zgraggen S, Mohaupt MG, Furrer H. Effect of tenofovir on renal glomerular and tubular function. AIDS 2007; 21: 1483-1485.
58. Onyeador N, Patel D, Lyall H et al. Renal tubular dysfunction associated with tenofovir-based HAART in perinatally acquired HIV: The need for paediatric formulations and pharmacokinetic studies. HIV Med 2008; 9(Suppl. 1): 26. [P61].
59. Lyons F, Hopkins S, Kelleher B et al. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. HIV Med 2006; 7: 255-260.
60. Jamisse L, Balkus J, Hitti J et al. Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens. J Acquir Immune Defic Syndr 2007; 44: 371-376.
61. Watts DH. Treating HIV during pregnancy: An update on safety issues. Drug Saf 2006; 29: 467-490.
62. Taiwo BO. Nevirapine toxicity. Int J STD AIDS 2006; 17: 364-369.
63. Manfredi R, Calza L, Chiodo F. Efavirenz vs. nevirapine in current clinical practice: A prospective, open-label observational study. J Acquir Immune Defic Syndr 2004; 35: 492-502.
64. Sustiva ® (efavirenz). US Prescribing Information. Princeton, NJ: Bristol-Myers Squibb, 2008.
65. ATRIPLA ®. Summary of Product Characteristics (December 2008). Foster City, CA: Gilead Sciences and Bristol-Myers Squibb, 2008.
66. ATRIPLA ® (efavirenz/emtricitabine/tenofovir disoproxil fumarate) tablets. US Prescribing Information. Foster City, CA: Gilead Sciences and Bristol-Myers Squibb, 2008.
67. Bequet R. Universal antiretroviral therapy for pregnant and breastfeeding HIV-infected women: Towards elimination of mother-to-child transmission of HIV-1 in resource limited settings. 5th Dominique Dormont International Conference. Paris, France, March 2009 [Abstract L7].